Park Place Capital Corp reduced its stake in Amgen Inc. (NASDAQ:AMGN – Free Report) by 6.1% during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 1,925 shares of the medical research company’s stock after selling 125 shares during the quarter. Park Place Capital Corp’s holdings in Amgen were worth $502,000 as of its most recent filing with the Securities and Exchange Commission (SEC).
Several other hedge funds have also bought and sold shares of AMGN. Capital Performance Advisors LLP purchased a new position in shares of Amgen during the third quarter valued at approximately $25,000. Legacy Investment Solutions LLC bought a new position in Amgen in the 3rd quarter worth $29,000. Hershey Financial Advisers LLC purchased a new stake in shares of Amgen in the 2nd quarter worth about $30,000. Matrix Trust Co purchased a new position in shares of Amgen during the third quarter valued at about $36,000. Finally, Livelsberger Financial Advisory bought a new position in Amgen in the third quarter worth about $56,000. 76.50% of the stock is currently owned by institutional investors.
Amgen Stock Down 0.0 %
NASDAQ:AMGN opened at $274.71 on Wednesday. The company has a debt-to-equity ratio of 7.55, a current ratio of 1.32 and a quick ratio of 0.96. Amgen Inc. has a 1-year low of $253.30 and a 1-year high of $346.85. The company has a 50-day moving average of $272.47 and a 200 day moving average of $306.67. The firm has a market cap of $147.66 billion, a PE ratio of 35.16, a price-to-earnings-growth ratio of 2.78 and a beta of 0.56.
Amgen Increases Dividend
The company also recently announced a quarterly dividend, which will be paid on Friday, March 7th. Investors of record on Friday, February 14th will be issued a dividend of $2.38 per share. This is an increase from Amgen’s previous quarterly dividend of $2.25. The ex-dividend date of this dividend is Friday, February 14th. This represents a $9.52 dividend on an annualized basis and a dividend yield of 3.47%. Amgen’s payout ratio is 115.24%.
Analyst Ratings Changes
Several analysts recently weighed in on the company. Piper Sandler cut their price target on Amgen from $344.00 to $310.00 and set an “overweight” rating on the stock in a research note on Thursday, January 2nd. Redburn Partners cut their target price on Amgen from $200.00 to $195.00 in a research note on Wednesday, November 27th. TD Cowen lifted their price target on Amgen from $381.00 to $383.00 and gave the stock a “buy” rating in a research report on Monday, October 21st. Cantor Fitzgerald reissued an “overweight” rating and set a $405.00 price objective on shares of Amgen in a research report on Tuesday, October 22nd. Finally, Leerink Partners decreased their target price on shares of Amgen from $349.00 to $302.00 in a report on Wednesday, November 27th. Two investment analysts have rated the stock with a sell rating, twelve have assigned a hold rating, thirteen have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat.com, Amgen currently has a consensus rating of “Hold” and an average price target of $314.91.
Read Our Latest Stock Analysis on Amgen
Amgen Profile
Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.
See Also
- Five stocks we like better than Amgen
- 10 Best Airline Stocks to Buy
- Tempus AI: A Game-Changer in AI-Powered Healthcare
- Learn Technical Analysis Skills to Master the Stock Market
- Pelosi Bets Big on AI: This Is What You Need to Know
- Do ETFs Pay Dividends? What You Need to Know
- Mobileye’s High Short Interest Signals Squeeze Potential
Want to see what other hedge funds are holding AMGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Amgen Inc. (NASDAQ:AMGN – Free Report).
Receive News & Ratings for Amgen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen and related companies with MarketBeat.com's FREE daily email newsletter.